Плейотропные эффекты левосимендана на сердце и другие органы

Автор: Ломиворотов В.В., Бобошко Владимир Александрович

Журнал: Патология кровообращения и кардиохирургия @journal-meshalkin

Рубрика: Обзоры

Статья в выпуске: 2 т.21, 2017 года.

Бесплатный доступ

Девосимендан - негликозидное кардиотоническое лекарственное средство, обладающее вазодилатирующими свойствами. К основным механизмам действия препарата относят увеличение чувствительности сократительных белков кардиомиоцитов к кальцию и способность открывать аденозинтрифосфат-зависимые калиевые каналы в гладких мышцах сосудистой стенки. В соответствии с рекомендациями Европейского общества кардиологов, показанием к использованию левосимендана является лечение острой декомпенсации тяжелой хронической сердечной недостаточности. С момента первого применения препарата (более 15 лет назад) обнаружены дополнительные плейотропные эффекты, которые не только влияют на состояние миокарда (при ишемии и ремоделировании), но и потенцируют органопротективные процессы за пределами сердечно-сосудистой системы. В ходе экспериментальных и клинических исследований выявлены механизмы, положительное влияющие на функцию легких, почек, печени, органов желудочно-кишечного тракта, центральной нервной системы, а также на процессы воспаления и сепсиса. В обзоре обобщены существующие исследования и доказательства плейотропных эффектов левосимендана, а также показаны потенциальные новые области его клинического применения.

Еще

Левосимендан, плейотропные эффекты, кардиотонические препараты, сердечная недостаточность, инфаркт миокарда, кардиогенный шок, кардиопротекция, органопротекция

Короткий адрес: https://sciup.org/142140793

IDR: 142140793   |   DOI: 10.21688-1681-3472-2017-2-14-28

Список литературы Плейотропные эффекты левосимендана на сердце и другие органы

  • Pollesello P., Papp Z., Papp J.G. Calcium sensitizers: what have we learned over the last 25 years? IntJ Cardiol. 2016;203:543-8. https://doi.org/10.1016/j.ijcard.2015.10.240
  • Haikala H., Kaivola J., Nissinen E., Wall P., Levijoki J., Lindén I.B. Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan. J Mol Cell Cardiol. 1995;27(9):1859-66.
  • Hasenfuss G., Pieske B., Castell M., Kretschmann B., Maier L.S., Just H. Influence of the novel inotropic agent levosimendan on isometric tension and calcium cycling in failing human myocardium. Circulation. 1998;98(20):2141-7.
  • Pagel P.S., McGough M.F., Hettrick D.A., Lowe D., Tessmer J.P., Jamali I.N., Warltier D.C. Levosimendan enhances left ventricular systolic and diastolic function in conscious dogs with pacing-induced cardiomyopathy. J Cardiovasc Pharmacol. 1997;29(5):563-73.
  • Tachibana H., Cheng H.J., Ukai T., Igawa A., Zhang Z.S., Little W.C., Cheng C.P. Levosimendan improves LV systolic and diastolic performance at rest and during exercise after heart failure. Am J Physiol Heart Circ Physiol. 2005;288(2):H914-22. https://doi.org/10.1152/ajpheart.00465.2004
  • Brixius K., Reicke S., Schwinger R.H. Beneficial effects of the Ca(2+) sensitize levosimendan in human myocardium. Am J Physiol Heart Circ Physiol. 2002;282(1):H131-7.
  • Givertz M.M., Andreou C., Conrad C.H., Colucci W.S. Direct myocardial effects of levosimendan in humans with left ventricular dysfunction: alteration of forcefrequency and relaxation-frequency relationships. Circulation. 2007;115(10):1218-24. https://doi. org/10.1161/CirculationAHA.106.668640
  • Parissis J.T., Panou F., Farmakis D., Adamopoulos S., Filippatos G., Paraskevaidis I., Venetsanou K., Lekakis J., Kremastinos D.T. Effects of levosimendan onmarkers of left ventricular diastolic function and neurohormonal activation in patients with advanced heart failure. Am J Cardiol. 2005;96(3):423-6. https://doi.org/10.1016/j. amjcard.2005.03.092
  • Malik V., Subramanian A., Hote M., Kiran U. Effect of levosimendan on diastolic function in patients undergoing coronary artery bypass grafting: a comparative study. J Cardiovasc Pharmacol. 2015;66(2):141-7. https://doi.org/10.1097/FJC.0000000000000256
  • Jorgensen K., Bech-Hanssen O., Houltz E., Ricksten S.E. Effects of levosimendan on left ventricular relaxation and early filling atmaintained preload and afterload conditions after aortic valve replacement for aortic stenosis. Circulation. 2008;117(8):1075-81. https://doi.org/10.1161/ href='contents.asp?titleid=14507' title='Circulation'>CirculationAHA.107.722868
  • Pagel P.S., Hettrick D.A., Warltier D.C. Comparison of the effects of levosimendan, pimobendan, and milrinone on canine left ventricular-arterial coupling and mechanical efficiency. Basic Res Cardiol. 1996;91(4):296-307.
  • Missant C., Rex S., Segers P., Wouters P.F. Levosimendan improves right ventriculovascular coupling in a porcine model of right ventricular dysfunction. Crit Care Med. 2007;35(3):707-15. https://doi.org/10.1097/01. CCM.0000257326.96342.57
  • Guarracino F., Cariello C., Danella A., Doroni L., Lapolla F., Stefani M., Baldassarri R., Vullo C. Effect of levosimendan on ventriculo-arterial coupling in patients with ischemic cardiomyopathy. Acta Anaesthesiol Scand. 2007;51 (9):1217-24. https://doi.org/10.1111/j.1399-6576.2007.01428x
  • Louhelainen M., Merasto S., Finckenberg P., Vahtola E., Kaheinen P., Leskinen H., Levijoki J., Pollesello P., Haikala H., Mervaala E.M. Effects of calcium sensitizer OR-1986 on a cardiovascular mortality and myocardial remodelling in hypertensive Dahl/Rapp rats. J Physiol Pharmacol. 2009;60(3):41-7.
  • Vahtola E., Storvik M., Louhelainen M., Merasto S., Lakkisto P., Lakkisto J., Tikkanen I., Kaheinen P., Levijoki J., Mervaala E. Effects of levosimendan on cardiac gene expression profile and post-infarct cardiac remodelling in diabetic Goto-Kakizaki rats. Basic Clin Pharmacol Toxicol 2011;109(5):387-97. https://doi.org/10.1111/j.1742-7843.2011.00743x
  • Okada M., Suzuki A., Yamawaki H., Hara Y. Levosimendaninhibitsinterleukin-1 p-induced cell migration and MMP-9 secretion in rat cardiac fibroblasts. Eur J Pharmacol. 2013;718(1-3):332-9. https://doi.org/10.1016Zj.ejphar.2013.08.013
  • Tziakas D.N., Chalikias G.K., Hatzinikolaou H.I., Stakos D.A., Papanas N., Tentes I.K., Kortsaris A.X., Maltezos E., Hatseras D.I., Kaski J.C. Levosimendan use reduces matrix metalloproteinase-2 in patients with decompensated heart failure. Cardiovasc Drugs Ther. 2005;19(6):399-402. https://doi.org/10.1007/s10557-005-5417-5
  • Metra M., Ponikowski P., Dickstein K., McMurray J.J., Gavazzi A., Bergh C.H., Fraser A.G., Jaarsma T., Pitsis A., Mohacsi P., Bohm M., Anker S., Dargie H., Brutsaert D., Komajda M. Heart Failure Association of the European Society of Cardiology. Advanced chronic heart failure: a position statement from the Study Group on Advanced Heart Failure of the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2007;9(6-7):684-94. https://doi.org/10.1016/j.ejheart.2007.04.003
  • Tuomainen P.O., Magga J., Timonen P., Miettinen K., Kurttila M., Vanninen E., Laitinen T., Timonen K., Punnonen K., Parviainen I., Uusaro A., Vuolteenaho O., Kivikko M., Peuhkurinen K. Intermittent levosimendan treatment in patients with severe congestive heart failure. Clin Res Cardiol. 2013;102(7):485-93. https://doi.org/10.1007/s00392-013-0554-5
  • Malfatto G., Della Rosa F., Villani A., Rella V., Branzi G., Facchini M., Parati G. Intermittent levosimendan infusions in advanced heart failure: favourable effects on left ventricular function, neurohormonal balance, and one-year survival. J Cardiovasc Pharmacol. 2012;60(5):450-5. https://doi.org/10.1097/FJC.0b013e31826b86aa
  • Silvetti S., Greco T., Di Prima A.L., Mucchetti M., de Lurdes C.M., Pasin L., Scandroglio M., Landoni G., Zangrillo A. Intermittent levosimendan improves midterm survival in chronic heart failure patients: meta-analysis of randomised trials. Clin Res Cardiol. 2014;103(7):505-13. https://doi.org/10.1007/s00392-013-0649-z
  • Altenberger J., Parissis J.T., Costard-Jaeckle A., Winter A., Ebner C., Karavidas A., Sihorsch K., Avgeropoulou E., Weber T., Dimopoulos L., Ulmer H., Poelzl G. Efficacy and safety of the pulsed infusions of levosimendan in outpatients with advanced heart failure (LevoRep) study: a multicentre randomized trial. Eur J Heart Fail. 2014;16(8):898-906. https://doi.org/10.1002/ejhf.118
  • Nieminen M.S., Altenberger J., Ben-Gal T., Bohmer A., Comin-Colet J., Dickstein K., Edes I., Fedele F., Fonseca C., Garcla-Gonzalez M.J., Giannakoulas G., Iakobishvili Z., Jaaskelainen P., Karavidas A., Kettner J., Kivikko M., Lund L.H., Matskeplishvili S.T., Metra M., Morandi F., Oliva F., Parkhomenko A., Parissis J., Pollesello P., Polzl G., Schwinger R.H., Segovia J., Seidel M., Vrtovec B., Wikstrom G. Repetitive use of levosimendan for treatment of chronic advanced heart failure: clinical evidence, practical considerations, and perspectives: an expert panel consensus. Int J Cardiol. 2014;174(2):360-7. https://doi.org/10.1016/j.ijcard.2014.04.111
  • Pollesello P., Papp Z. The cardioprotective effects of levosimendan: preclinical and clinical evidence. J Cardiovasc Pharmacol. 2007;50(3):257-63. https://doi.org/10.1097/FJC.0b013e3180986230
  • Honisch A., Theuring N., Ebner B., Wagner C., Strasser R.H., Weinbrenner C. Postconditioning with levosimendan reduces the infarct size involving the PI3K pathway and KATP-channel activation but is independent of PDE-III inhibition. Basic Res Cardiol. 2010;105(2):155-67. https://doi.org/10.1007/s00395-009-0064-9
  • Metzsch C., Linner R., Steen S., Liao Q., Algotsson L. Levosimendan cardioprotection in acutely beta-1 adrenergic receptor blocked open chest pigs. Acta Anaesthesiol Scand. 2010;54(1):103-10. https://doi.org/10.1111/j.1399-6576.2009.02070.x
  • Das B., Sarkar C. Pharmacological preconditioning by levosimendan is mediated by inducible nitric oxide synthase and mitochondrial KATP channel activation in the in vivo anesthetized rabbit heart model. Vasc Pharmacol. 2007;47(4):248-56. https://doi. org/10.1016/j.vph.2007.06.008
  • du Toit E.F., Genis A., Opie L.H., Pollesello P., Lochner A. A role for the RISK pathway and K(ATP) channels in pre-and postconditioning induced by levosimendan in the isolated guinea pig heart. Br J Pharmacol. 2008;154(1):41-50. https://doi.org/10.1038/bjp.2008.52
  • Tritapepe L., De Santis V., Vitale D., Santulli M., Morelli A., Nofroni I., Puddu P.E., Singer M., Pietropaoli P. Preconditioning effects of levosimendan in coronary artery bypass grafting-a pilot study. Br J Anaesth. 2006;96(6):694-700. https://doi.org/10.1093/bja/ael082
  • Sonntag S., Sundberg S., Lehtonen L.A., Kleber F.X. The calcium sensitizer levosimendan improves the function of stunned myocardium after percutaneous transluminal coronary angioplasty in acute myocardial ischemia. J Am Coll Cardiol. 2004;43(12):2177 82. https://doi.org/10.1016Zj.jacc.2004.02.052
  • De Luca L., Sardella G., Proietti P., Battagliese A., Benedetti G., Di Roma A., Fedele F. Effects of levosimendan on left ventricular diastolic function after primary angioplasty for acute anterior myocardial infarction: a Doppler echocardiographic study. J Am Soc Echocardiogr. 2006;19(2):172-7. https://doi.org/10.1016/j. echo.2005.08.016
  • Grossini E., Molinari C., Caimmi P.P., Uberti F., Vacca G. Levosimendan induces NO production through p38 MAPK, ERK and Akt in porcine coronary endothelial cells: role for mitochondrial K(ATP) channel. Br] Pharmacol. 2009;156(2):250-61. https://doi.org/10.1111/j.1476-5381.2008.00024.x
  • Ambrus N., Szolnoky J., Pollesello P., Kun A., Varro A., Papp J.G., Pataricza J. Prolonged antispasmodic effect in isolated radial artery graft and pronounced platelet inhibition induced by the inodilator drug, levosimendan. Basic Clin Pharmacol Toxicol. 2012;110(3):269 74. https://doi.org/10.1111/j.1742-7843.2011.00801.x
  • Greenberg G., Cohen E., Garty M., Iakobishvili Z., Sandach A., Behar S. Outcomes of acute heart failure associated with acute coronary syndrome versus other causes. Acute Card Care. 2011;13(2):87-92. https://doi.org/10.3109/17482941.2011.567284
  • Moiseyev V.S., Poder P., Andrejevs N., Ruda M.Y., Golikov A.P., Lazebnik L.B. Safety and efficacy of a novel calcium sensitizer, levosimendan, in patients with left ventricular failure due to an acute myocardial infarction. A randomized, placebo-controlled, double-blind study (RUSSLAN). Eur Heart J. 2002;23(18):1422-32.
  • Husebye T., Eritsland J., Muller C., Sandvik L., Arnesen H., Seljeflot I. Levosimendan in acute heart failure following primary percutaneous coronary intervention-treated acute ST-elevation myocardial infarction. Results from the LEAF trial: a randomized, placebo-controlled study. Eur J Heart Fail. 2013;15(5):565-72. https://doi.org/10.1093/eurjhf/hfs215
  • Wu X., Wu J., Yan X., Zhang Y. Enhancement of myocardial function and reduction of injury with levosimendan after percutaneous coronary intervention for acute myocardial infarction: a pilot study. Cardiology. 2013;15(5):565-72. https://doi.org/10.1093/eurjhf/hfs215
  • Mebazaa A., Nieminen M.S., Packer M., Cohen-Solal A., Kleber F.X., Pocock S.J. Levosimendan vs dobutamine for patients with acute decompensated heart failure: the SURVIVE Randomized Trial. JAMA. 2007;297(17):1883-91. https://doi.org/10.1001/JAMA.297.17.1883
  • Dominguez-Rodriguez A., Samimi-Fard S., Garcia-Gonzalez M.J., Abreu-Gonzalez P. Effects of levosimendan versus dobutamine on left ventricular diastolic function in patients with cardiogenic shock after primary angioplasty. Int J Cardiol. 2008;128(2):214-7.
  • Landoni G., Biondi-Zoccai G., Greco M., Greco T., Bignami E., Morelli A. Effects of levosimendan on mortality and hospitalization. A meta-analysis of randomized controlled studies. Crit Care Med. 2012;40(2):634-46. https://doi.org/10.1097/CCM.0b013e318232962a
  • Koster G., Wetterslev J., Gluud C., Zijlstra J.G., Scheeren T.W., van der Horst I.C. Effects of levosimendan for low cardiac output syndrome in critically ill patients: systematic review with meta-analysis and trial sequential analysis. Intensive Care Med. 2015;41(2):203-21. https://doi.org/10.1007/s00134-014-3604-1
  • Nieminen M.S., Buerke M., Cohen-Solal A., Costa S., Édes I., Erlikh A., Franco F., Gibson C., Gorjup V., Guarracino F., Gustafsson F., Harjola V.P., Husebye T., Karason K., Katsytadze I., Kaul S., Kivikko M., Marenzi G., Masip J., Matskeplishvili S., Mebazaa A., Moller J.E., Nessler J., Nessler B., Ntalianis A., Oliva F., Pichler-Cetin E., Pôder P., Recio-Mayoral A., Rex S., Rokyta R., Strasser R.H., Zima E., Pollesello P. The role of levosimendan in acute heart failure complicating acute coronary syndrome: A review and expert consensus opinion. Int J Cardiol. 2016;218:150-7. https://doi. org/10.1016/j.ijcard.2016.05.009
  • Lomivorotov V.V., Boboshko V.A., Efremov S.M., Kornilov I.A., Chernyavskiy A.M., Lomivorotov V.N., Knazkova L.G., Karaskov A.M. Levosimendan versus an intra-aortic balloon pump in high-risk cardiac patients. J Cardiothorac Vasc Anesth. 2011;19(2):154-9. https://doi.org/10.1177/0218492311401143
  • Toller W., Heringlake M., Guarracino F., Algotsson L., Alvarez J., Argyriadou H., Ben-Gal T., Cerny V., Cholley B., Eremenko A., Guerrero-Orriach J.L., Jarvela K., Karanovic N., Kivikko M., Lahtinen P., Lomivorotov V., Mehta R.H., Music S., Pollesello P., Rex S., Riha H., Rudiger A., Salmenpera M., Szudi L., Tritapepe L., Wyncoll D., Owall A. Preoperative and perioperative use of levosimendan in cardiac surgery: European expert opinion. IntJ Cardiol. 2015;184:323-36. https://doi.org/10.1016/j.ijcard.2015.02.022
  • Morelli A., Ertmer C., Pietropaoli P., Westphal M. Reducing the risk of major elective non-cardiac surgery: is there a role for levosimendan in the preoperative optimization of cardiac function? Curr Drug Targets. 2009;10(9):863-71.
  • Чернявский А.М., Несмачный А.С., Рузматов Т.М., Бобошко А.В., Николаев Д.А., Бобошко В.А., Эфендиев В.У., Подсосникова Т.Н. Хирургическое лечение ишемической болезни сердца у пациентов с низкой фракцией выброса левого желудочка на работающем сердце в условиях искусственного кровообращения: непосредственные результаты. Патология кровообращения и кардиохирургия. 2015;19(1):51-8. http://dx.doi. org/10.21688/1681-3472-2015-1-51-58 DOI: rg/10.21688/1681-3472-2015-1-51-58]
  • Grossini E., Molinari C., Pollesello P., Bellomo G., Valente G., Mary D., Vacca G., Caimmi P. Levosimendan protection against kidney ischemia/reperfusion injuries in anesthetized pigs. J Pharmacol Exp Ther. 2012;342(2):376-88. http://dx.doi.org/10.1124/jpet.112.193961
  • Gecit I., Kavak S., Yuksel M.B., Basel H., Bektas H., Gumrukcuoglu H.A., Meral I., Demir H. Effect of short-term treatment with levosimendan on oxidative stress in renal tissues of rats. Toxicol Ind Health. 2014;30:47-51. http://dx.doi. org/10.1177/0748233712451773
  • Zager R.A., Johnson A.C., Lund S., Hanson S.Y., Abrass C.K. Levosimendan protects against experimental endotoxemic acute renal failure. Am J Physiol Ren Physiol. 2006;290(6):F1453-62. http://dx.doi.o DOI: rg/10.1152/ajprenal.00485.2005
  • Bragadottir G., Redfors B., Ricksten S.E. Effects of levosimendan on glomerular filtration rate, renal blood flow, and renal oxygenation after cardiac surgery with cardiopulmonary bypass: a randomized placebo-controlled study. Crit Care Med. 2013;41(10):2328-35. http://dx.doi.o DOI: rg/10.1097/CCM.0b013e31828e946a
  • Baysal A., Yanartas M., Dogukan M., Gundogus N., Kocak T., Koksal C. Levosimendan improves renal outcome in cardiac surgery: a randomized trial. J Cardiothorac Vasc Anesth. 2014;28(3):586-94. http://dx.doi.o DOI: rg/10.1053/j.jvca.2013.09.004
  • Fedele F., Bruno N., Brasolin B., Caira C., D'Ambrosi A., Mancone M. Levosimendan improves renal function in acute decompensated heart failure: possible underlying mechanisms. Eur J Heart Fail. 2014;16(3):281-8. http://dx.doi.o DOI: rg/10.1002/ejhf.9
  • Niu Z.Z., Wu S.M., Sun W.Y., Hou W.M., Chi Y.F. Perioperative levosimendan therapy is associated with a lower incidence of acute kidney injury after cardiac surgery: a meta-analysis. J Cardiovasc Pharmacol. 2014;63(2):107-12. http://dx.doi.org/10.1097/FJC.0000000000000028
  • Zhou C., Gong J., Chen D., Wang W., Liu M., Liu B. Levosimendan for prevention of acute kidney injury after cardiac surgery: a meta-analysis of randomized controlled trials. Am J Kidney Dis. 2016;67(3):408-16. http://dx.doi.o DOI: rg/10.1053Zj.ajkd.2015.09.015
  • Bove T., Matteazzi A., Belletti A., Paternoster G., Saleh O., Taddeo D., Dossi R., Greco T., Bradic N., Husedzinovic I., Nigro Neto C., Lomivorotov V., Calabro M.G. Beneficial impact of levosimendan in critically ill patients with or at risk for acute renal failure: a meta-analysis of randomized clinical trials. Heart Lung Vessel. 2015;7(1):35-4.
  • Yilmaz M.B., Yalta K., Yontar C., Karadas F., Erdem A., Turgut O.O., Yilmaz A., Tandogan I. Levosimendan improves renal function in patients with acute decompensated heart failure: comparison with dobutamine. Cardiovasc Drugs Ther. 2007;21(6):431-5. http://dx.doi. org/10.1007/s10557-007-6066-7
  • Rafouli-Stergiou P., Parissis J.T., Farmakis D., Bistola V., Frogoudaki A., Vasiliadis K., Ikonomidis I., Paraskevaidis I., Kremastinos D., Filippatos G., Lekakis J. Effects of levosimendan on markers of kidney function in patients with acutely decompensated heart failure and renal impairment. J Cardiovasc Med (Hagerstown). 2015. http://dx.doi.o DOI: rg/10.2459/JCM.0000000000000244
  • Grossini E., Pollesello P., Bellofatto K., Sigaudo L., Farruggio S., Origlia V., Mombello C., Mary D.A., Valente G., Vacca G. Protective effects elicited by levosimendan against liver ischemia/reperfusion injury in anesthetized rats. Liver Transpl. 2014;20(3):361-75. http://dx.doi.o DOI: rg/10.1002/lt.23799
  • Pagel P.S., Hettrick D.A., Warltier D.C. Influence of levosimendan, pimobendan, and milrinone on the regional distribution of cardiac output in anaesthetized dogs. Br J Pharmacol. 1996;119(3):609-15.
  • Garcia-Septien J., Lorente J.A., Delgado M.A., de Paula M., Nin N., Moscoso A., Sanchez-Ferrer A., Perez-Vizcaino F., Esteban A. Levosimendan increases portal blood flow and attenuates intestinal intramucosal acidosis in experimental septic Shock. Shock. 2010;34(3):275-80. http://dx.doi.org/10.1097/SHK.0b013e3181cd8c5b
  • Alvarez J., Baluja A., Selas S., Otero P., Rial M., Veiras S., Caruezo V., Taboada M., Rodriguez I., Castroagudin J., Tome S., Rodriguez A., Rodriguez J. A comparison of dobutamine and levosimendan on hepatic blood flow in patients with a low cardiac output state after cardiac surgery: a randomised controlled study. Anaesth Intensive Care. 2013;41(6):719-27.
  • Schwarte L.A., Picker O., Bornstein S.R., Fournell A., Scheeren T.W. Levosimendan is superior to milrinone and dobutamine in selectively increasing microvascular gastric mucosal oxygenation in dogs. Crit Care Med. 2005;33(1):135-42;discussion 246-7.
  • Cunha-Goncalves D., Perez-de-Sa V., Grins E., Dahm P.L., Thorne J., Blomquist S. Inotropic support during experimental endotoxemic shock: part I. The effects of levosimendan on splanchnic perfusion. Anesth Analg. 2009;109(5):1568-75. http://dx.doi.org/10.1213/ane.0b013e3181af3fe3
  • Leppikangas H., Tenhunen J.J., Lindgren L., Salenius J.P., Ruokonen E. Effects of levosimendan on indocyanine green plasma disappearance rate and the gastric mucosal-arterial pCO2 gradient in abdominal aortic aneurysm surgery. Acta Anaesthesiol Scand. 2008;52(6):785 92. http://dx.doi.o DOI: rg/10.1111/j.1399-6576.2008.01659.x
  • Zhang C., Guo Z., Liu H., Shi Y., Ge S. Influence of levosimendan postconditioning on apoptosis of rat lung cells in a model of ischemia-reperfusion injury. PLoS One. 2015;10(1):e0114963. http://dx.doi.o DOI: rg/10.1371/journal.pone.0114963
  • Rieg A.D., Rossaint R., Verjans E., Maihofer N.A., Uhlig S., Martin C. Levosimendan relaxes pulmonary arteries and veins in precision-cut lung slices -the role of KATP-channels, cAMP and cGMP. PLoS One. 2013;8(6):e66195. http://dx.doi.o. pone.0066195 DOI: rg/10.1371/journal
  • Morelli A., Teboul J.L., Maggiore S.M., Vieillard-Baron A., Rocco M., Conti G., De Gaetano A., Picchini U., Orecchioni A., Carbone I., Tritapepe L., Pietropaoli P., Westphal M. Effects of levosimendan on right ventricular afterload in patients with acute respiratory distress syndrome: a pilot study. Crit Care Med. 2006;34(9):2287 93. http://dx.doi.o DOI: rg/10.1097/01.CCM.0000230244.17174.4F
  • Ottenheijm C.A., Heunks L.M., Sieck G.C., Zhan W.Z., Jansen S.M., Degens H., de Boo T., Dekhuijzen P.N. Diaphragm dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2005;172(2):200-5. http://dx.doi.o DOI: rg/10.1164/rccm.200502-262OC
  • van Hees H.W., Dekhuijzen P.N., Heunks L.M. Levosimendan enhances force generation of diaphragm muscle from patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;179(1):41-7. http://dx.doi.o DOI: rg/10.1164/rccm.200805-732OC
  • Schellekens W.J., van Hees H.W., Linkels M., Dekhuijzen P.N., Scheffer G.J., van der Hoeven J.G., Heunks L.M. Levosimendan affects oxidative and inflammatory path-ways in the diaphragm of ventilated endotoxemic mice. Crit Care. 2015;19:69. http://dx.doi. org/10.1186/s13054-015-0798-8
  • Doorduin J., Sinderby C.A., Beck J., Stegeman D.F., van Hees H.W., van der Hoeven J.G., Heunks L.M. The calcium sensitizer levosimendan improves human diaphragm function. Am J Respir Crit Care Med. 2012;185(1):90-5. http://dx.doi.org/10.1164/rccm.201107-1268OC
  • Fournell A., Scheeren T.W., Picker O., Schwarte L.A. Pharmacologic interventions to improve splanchnic oxygenation during ventilation with positive end-expiratory pressure. Adv Exp Med Biol. 2012;737:235-8. http://dx.doi.o DOI: rg/10.1007/978-1-4614-1566-4_34
  • Affronti A., di Bella I., Carino D., Ragni T. Levosimendan may improve weaning outcomes in venoarterial ECMO patients. ASAIO J. 2013;59(6):554-7. http://dx.doi.o DOI: rg/10.1097/MAT.0b013e3182a4b32e
  • Eriksson H.I., Jalonen J.R., Heikkinen L.O., Kivikko M., Laine M., Leino K.A., Kuitunen A.H., Kuttila K.T., Perakyla T.K., Sarapohja T., Suojaranta-Ylinen R.T., Valtonen M., Salmenpera M.T. Levosimendan facilitates weaning from cardiopulmonary bypass in patients undergoing coronary artery bypass grafting with impaired left ventricular function. Ann Thorac Surg. 2009;87(2):448-54. http://dx.doi.o DOI: rg/10.1016/j.athoracsur.2008.10.029
  • Roehl A.B., Hein M., Loetscher P.D., Rossaint J., Weis J., Rossaint R., Coburn M. Neuroprotective properties of levosimendan in an in vitro model of traumatic brain injury. BMC Neurol. 2010;10:97. http://dx.doi.o DOI: rg/10.1186/1471-2377-10-97
  • Hein M., Zoremba N., Bleilevens C., Bruells C., Rossaint R., Roehl A.B. Levosimendan limits reperfusion injury in a rat middle cerebral artery occlusion (MCAO) model. BMC Neurol. 2013;13:106. http://dx.doi.o DOI: rg/10.1186/1471-2377-13-106
  • Katircioglu S.F., Seren M., Parlar A.I., Turan N.N., Manavbasi Y., Aydog G., Cicekcioglu F., Tutun U., Ulus A.T. Levosimendan effect on spinal cord ischemia-reperfusion injury following aortic clamping. J Card Surg. 2008;23(1):44-8. http://dx.doi.org/10.1111/j.1540-8191.2007.00486.x
  • Roehl A.B., Zoremba N., Kipp M., Schiefer J., Goetzenich A., Bleilevens C., Kuehn-Velten N., Tolba R., Rossaint R., Hein M. The effects of levosimendan on brain metabolism during initial recovery from global transient ischaemia/hypoxia. BMC Neurol. 2012;12:81. http://dx.doi.o DOI: rg/10.1186/1471-2377-12-81
  • Bravo M.C., Lopez P., Cabanas F., Perez-Rodriguez J., Perez-Fernandez E., Quero J., Pellicer A. Acute effects of levosimendan on cerebral and systemic perfusion and oxygenation in newborns: an observational study. Neonatology. 2011;99(3):217-23. http://dx.doi.o DOI: rg/10.1159/000314955
  • Kivikko M., Kuoppamaki M., Soinne L., Sundberg S., Pohjanjousi P., Ellmen J., Roine R.O. Oral levosimendan increases cerebral blood flow velocities in patients with a history of stroke or transient ischemic attack: a pilot safety study. Curr Ther Res Clin Exp. 2015;77:46-51. http://dx.doi.o DOI: rg/10.1016/j.curtheres.2015.01.001
  • Varvarousi G., Xanthos T., Sarafidou P., Katsioula E., Georgiadou M., Eforakopoulou M., Pavlou H. Role of levosimendan in the management of subarachnoid hemorrhage. Am J Emerg Med. 2016;34(2):298-306. http://dx.doi.o DOI: rg/10.1016/j.ajem.2015.11.024
  • Cengiz S.L., Erdi M.F., Tosun M., Atalik E., Avunduk M.C., Sonmez F.C., Mehmetoglu I., Baysefer A. Beneficial effects of levosimendan on cerebral vasospasm induced by subarachnoid haemorrhage: an experimental study. Brain Inj. 2010;24(6):877-85. http://dx.doi. org/10.3109/02699051003789260
  • Busani S., Rinaldi L., Severino C., Cobelli M., Pasetto A., Girardis M. Levosimendan in cardiac failure after subarachnoid hemorrhage. J Trauma. 2010;68(5):E108-10. http://dx.doi.org/10.1097/TA.0b013e31817c4284
  • Parissis J.T., Karavidas A., Bistola V., Arapi S., Paraskevaidis I.A., Farmakis D., Korres D., Filippatos G., Matsakas E., Kremastinos D.T. Effects of levosimendan on flow-mediated vasodilation and soluble adhesion molecules in patients with advanced chronic heart failure. Atherosclerosis. 2008;197(1):278-82.
  • Krychtiuk K.A., Watzke L., Kaun C., Buchberger E., Hofer-Warbinek R., Demyanets S., Pisoni J., Kastl S.P., Rauscher S., Groger M., Aliabadi A., Zuckermann A., Maurer G., de Martin R., Huber K., Wojta J., Speidl W.S. Levosimendan exerts anti-inflammatory effects on cardiac myocytes and endothelial cells in vitro. Thromb Haemost. 2015;113(2):350-62. http://dx.doi.o DOI: rg/10.1160/TH14-06-0549
  • Hasslacher J., Bijuklic K., Bertocchi C., Kountchev J., Bellmann R., Dunzendorfer S., Joannidis M. Levosimendan inhibits release of reactive oxygen species in polymorphonuclear leukocytes in vitro and in patients with acute heart failure and septic shock: a prospective observational study. Crit Care. 2011;15(4):R166. http://dx.doi.o DOI: rg/10.1186/cc10307
  • Trikas A., Antoniades C., Latsios G., Vasiliadou K., Karamitros I., Tousoulis D., Tentolouris C., Stefanadis C. Long-term effects of levosimendan infusion on inflammatory processes and sFas in patients with severe heart failure. Eur J Heart Fail. 2006 Dec;8(8):804-9. http://dx.doi.o DOI: rg/10.1016/j.ejheart.2006.03.003
  • Tsao C.M., Li K.Y., Chen S.J., Ka S.M., Liaw W.J., Huang H.C., Wu C.C. Levosimendan attenuates multiple organ injury and improves survival in peritonitis-induced septic shock: studies in a rat model. Crit Care. 2014;18(6):652. http://dx.doi.o DOI: rg/10.1186/s13054-014-0652-4
  • Wang Q., Yokoo H., Takashina M., Sakata K., Ohashi W., Abedelzaher L.A., Imaizumi T., Sakamoto T., Hattori K., Matsuda N., Hattori Y. Anti-inflammatory profile of levosimendan in cecal ligation-induced septic mice and in lipopolysaccha-ride-stimulated macrophages. Crit Care Med. 2015;43(11):e508-20. http://dx.doi. org/10.1097/CCM.0000000000001269
  • Zangrillo A., Putzu A., Monaco F., Oriani A., Frau G., De Luca M., Di Tomasso N., Bignami E., Lomivorotov V., Likhvantsev V., Landoni G. Levosimendan reduces mortality in patients with severe sepsis and septic shock: a meta-analysis of randomized trials. J Crit Care. 2015;30(5):908-13. http://dx.doi.o DOI: rg/10.1016/j.jcrc.2015.05.017
  • Morelli A., De Castro S., Teboul J.L., Singer M., Rocco M., Conti G., De Luca L., Di Angelantonio E., Orecchioni A., Pandian N.G., Pietropaoli P. Effects of levosimendan on systemic and regional hemodynamics in septic myocardial depression. Intensive Care Med. 2005;31(5):638-44. http://dx.doi.o DOI: rg/10.1007/s00134-005-2619-z
  • Morelli A., Donati A., Ertmer C., Rehberg S., Lange M., Orecchioni A., Cecchini V., Landoni G., Pelaia P., Pietropaoli P., Van Aken H., Teboul J.L., Ince C., Westphal M. Levosimendan for resuscitating the microcirculation in patients with septic shock: a randomized controlled study. Crit Care. 2010;14(6):R232. http://dx.doi. org/10.1186/cc9387
  • Torraco A., Carrozzo R., Piemonte F., Pastore A., Tozzi G., Verrigni D., Assenza M., Orecchioni A., D'Egidio A., Marraffa E., Landoni G., Bertini E., Morelli A. Effects of levosimendan on mitochondrial function in patients with septic shock: a randomized trial. Biochimie. 2014;102:166-73. http://dx.doi.o DOI: rg/10.1016/j.biochi.2014.03.006
  • Gordon A.C., Perkins G.D., Singer M., McAuley D.F., Orme R.M., Santhakumaran S., Mason A.J., Cross M., Al-Beidh F., Best-Lane J., Brealey D., Nutt C.L., McNamee J.J., Reschreiter H., Breen A., Liu K.D., Ashby D. Levosimendan for the prevention of acute organ dysfunction in sepsis. N Engl J Med. 2016;375(17):1638-1648. http://dx.doi.o DOI: rg/10.1056/NEJMoa1609409
Еще
Статья обзорная